X

Trial Profile

A clinical trial to evaluate Safety and Immunogenicity of combination of AZD1222 and rAd26-S for the Prevention of COVID 19

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1222 (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics

Most Recent Events

24 Aug 2021 New trial record
20 Aug 2021 Interim results (n=20), presented in the Russian Direct Investment Fund Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com